{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:43:19Z","timestamp":1791186199150,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heritable pulmonary arterial hypertension (HPAH) is a serious lung vascular disease caused by heterozygous mutations in the bone morphogenetic protein (BMP) pathway genes, BMPR2 and SMAD9. One noncanonical function of BMP signaling regulates biogenesis of a subset of microRNAs. We have previously shown that this function is abrogated in patients with HPAH, making it a highly sensitive readout of BMP pathway integrity. Ataluren (PTC124) is an investigational drug that permits ribosomal readthrough of premature stop codons, resulting in a full-length protein. It exhibits oral bioavailability and limited toxicity in human trials. Here, we tested ataluren in lung- or blood-derived cells from patients with HPAH with nonsense mutations in BMPR2 (n = 6) or SMAD9 (n = 1). Ataluren significantly increased BMP-mediated microRNA processing in six of the seven cases. Moreover, rescue was achieved even for mutations exhibiting significant nonsense-mediated mRNA decay. Response to ataluren was dose dependent, and complete correction was achieved at therapeutic doses currently used in clinical trials for cystic fibrosis. BMP receptor (BMPR)-II protein levels were normalized and ligand-dependent phosphorylation of downstream target Smads was increased. Furthermore, the usually hyperproliferative phenotype of pulmonary artery endothelial and smooth muscle cells was reversed by ataluren. These results indicate that ataluren can effectively suppress a high proportion of BMPR2 and SMAD9 nonsense mutations and correct BMP signaling in vitro. Approximately 29% of all HPAH mutations are nonsense point mutations. In light of this, we propose ataluren as a potential new personalized therapy for this significant subgroup of patients with PAH.<\/jats:p>","DOI":"10.1165\/rcmb.2013-0100oc","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T07:45:27Z","timestamp":1369295127000},"page":"403-409","source":"Crossref","is-referenced-by-count":103,"title":["Correction of Nonsense\n                    <i>BMPR2<\/i>\n                    and\n                    <i>SMAD9<\/i>\n                    Mutations by Ataluren in Pulmonary Arterial Hypertension"],"prefix":"10.1093","volume":"49","author":[{"given":"Kylie M.","family":"Drake","sequence":"first","affiliation":[{"name":"Genomic Medicine Institute and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Dunmore","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke\u2019s and Papworth Hospitals, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren N.","family":"McNelly","sequence":"additional","affiliation":[{"name":"Genomic Medicine Institute and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.","family":"Morrell","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke\u2019s and Papworth Hospitals, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheala A.","family":"Aldred","sequence":"additional","affiliation":[{"name":"Genomic Medicine Institute and"},{"name":"Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,9,1]]},"reference":[{"key":"2026021904210465300_bib1","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1164\/rccm.201205-0886OC","article-title":"Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension","volume":"186","author":"Larkin","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021904210465300_bib2","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026021904210465300_bib3","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jacc.2009.04.015","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"54","author":"Machado","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026021904210465300_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/303059","article-title":"Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene","volume":"67","author":"Deng","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2026021904210465300_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"Lane","year":"2000","journal-title":"Nat Genet"},{"key":"2026021904210465300_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/humu.20285","article-title":"Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension","volume":"27","author":"Machado","year":"2006","journal-title":"Hum Mutat"},{"key":"2026021904210465300_bib7","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1136\/jmg.2004.023101","article-title":"Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension","volume":"41","author":"Koehler","year":"2004","journal-title":"J Med Genet"},{"key":"2026021904210465300_bib8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/humu.9251","article-title":"BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension","volume":"23","author":"Morisaki","year":"2004","journal-title":"Hum Mutat"},{"key":"2026021904210465300_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1053-2498(00)00352-1","article-title":"Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway specificity","volume":"20","author":"Trembath","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"2026021904210465300_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/jmg.40.12.865","article-title":"Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia","volume":"40","author":"Harrison","year":"2003","journal-title":"J Med Genet"},{"key":"2026021904210465300_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1183\/09031936.04.00085504","article-title":"Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia","volume":"23","author":"Abdalla","year":"2004","journal-title":"Eur Respir J"},{"key":"2026021904210465300_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/01.CIR.0000153798.78540.87","article-title":"Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood","volume":"111","author":"Harrison","year":"2005","journal-title":"Circulation"},{"key":"2026021904210465300_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/thx.2007.076109","article-title":"Early-life pulmonary arterial hypertension with subsequent development of diffuse pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia type 1","volume":"63","author":"Mache","year":"2008","journal-title":"Thorax"},{"key":"2026021904210465300_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/jmg.2008.062703","article-title":"A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension","volume":"46","author":"Shintani","year":"2009","journal-title":"J Med Genet"},{"key":"2026021904210465300_bib15","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/humu.21605","article-title":"Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension","volume":"32","author":"Nasim","year":"2011","journal-title":"Hum Mutat"},{"key":"2026021904210465300_bib16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1164\/rccm.201106-1130OC","article-title":"Altered microRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8","volume":"184","author":"Drake","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021904210465300_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature07086","article-title":"SMAD proteins control DROSHA-mediated microRNA maturation","volume":"454","author":"Davis","year":"2008","journal-title":"Nature"},{"key":"2026021904210465300_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.molcel.2010.07.011","article-title":"Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha","volume":"39","author":"Davis","year":"2010","journal-title":"Mol Cell"},{"key":"2026021904210465300_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270006297140","article-title":"Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers","volume":"47","author":"Hirawat","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"2026021904210465300_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"2026021904210465300_bib21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"2026021904210465300_bib22","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021904210465300_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/09031936.00120910","article-title":"Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis","volume":"38","author":"Wilschanski","year":"2011","journal-title":"Eur Respir J"},{"key":"2026021904210465300_bib24","doi-asserted-by":"crossref","first-page":"L789","DOI":"10.1152\/ajplung.90306.2008","article-title":"High levels of hyaluronan in idiopathic pulmonary arterial hypertension","volume":"295","author":"Aytekin","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026021904210465300_bib25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1165\/rcmb.2011-0416TE","article-title":"Human primary lung endothelial cells in culture","volume":"46","author":"Comhair","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026021904210465300_bib26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1164\/rccm.200810-1662OC","article-title":"Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension","volume":"180","author":"Toshner","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021904210465300_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/humu.9398","article-title":"BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension","volume":"27","author":"Aldred","year":"2006","journal-title":"Hum Mutat"},{"key":"2026021904210465300_bib28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2353\/ajpath.2008.070705","article-title":"Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension","volume":"172","author":"Asosingh","year":"2008","journal-title":"Am J Pathol"},{"key":"2026021904210465300_bib29","doi-asserted-by":"crossref","first-page":"15794","DOI":"10.1074\/jbc.M109.002881","article-title":"Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor\u2013like kinase-1 in human pulmonary artery endothelial cells","volume":"284","author":"Upton","year":"2009","journal-title":"J Biol Chem"},{"key":"2026021904210465300_bib30","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.10-1293","article-title":"Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension","volume":"139","author":"Kane","year":"2011","journal-title":"Chest"},{"key":"2026021904210465300_bib31","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"2026021904210465300_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1753465808094762","article-title":"Therapeutic advances in pulmonary arterial hypertension","volume":"2","author":"Boutet","year":"2008","journal-title":"Ther Adv Respir Dis"},{"key":"2026021904210465300_bib33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2010.11.020","article-title":"Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective","volume":"57","author":"Gomberg-Maitland","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026021904210465300_bib34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/pr.111.005587","article-title":"The pharmacological treatment of pulmonary arterial hypertension","volume":"64","author":"Frumkin","year":"2012","journal-title":"Pharmacol Rev"},{"key":"2026021904210465300_bib35","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1161\/CIRCULATIONAHA.105.601930","article-title":"Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension","volume":"113","author":"Elliott","year":"2006","journal-title":"Circulation"},{"key":"2026021904210465300_bib36","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1164\/rccm.200712-1807OC","article-title":"Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation","volume":"177","author":"Sztrymf","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021904210465300_bib37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.healun.2008.02.009","article-title":"Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension","volume":"27","author":"Rosenzweig","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"2026021904210465300_bib38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1183\/09031936.00187310","article-title":"Targeted gene delivery of BMPR2 attenuates pulmonary hypertension","volume":"39","author":"Reynolds","year":"2012","journal-title":"Eur Respir J"},{"key":"2026021904210465300_bib39","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021904210465300_bib40","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N Engl J Med"},{"key":"2026021904210465300_bib41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1172\/JCI7866","article-title":"Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice","volume":"104","author":"Barton-Davis","year":"1999","journal-title":"J Clin Invest"},{"key":"2026021904210465300_bib42","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.1023","article-title":"Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations","volume":"49","author":"Wagner","year":"2001","journal-title":"Ann Neurol"},{"key":"2026021904210465300_bib43","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/hmg\/ddn059","article-title":"Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension","volume":"17","author":"Nasim","year":"2008","journal-title":"Hum Mol Genet"},{"key":"2026021904210465300_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1399-0004.2009.01311.x","article-title":"Transcripts from a novel BMPR2 termination mutation escape nonsense mediated decay by downstream translation re-initiation: implications for treating pulmonary hypertension","volume":"77","author":"Hamid","year":"2010","journal-title":"Clin Genet"},{"key":"2026021904210465300_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view","volume":"79","author":"Lopez-Novoa","year":"2011","journal-title":"Kidney Int"},{"key":"2026021904210465300_bib46","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/MOO.0b013e32833e05ec","article-title":"Cellular mechanisms of aminoglycoside ototoxicity","volume":"18","author":"Warchol","year":"2010","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"2026021904210465300_bib47","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"key":"2026021904210465300_bib48","doi-asserted-by":"crossref","first-page":"37641","DOI":"10.1074\/jbc.M110.132415","article-title":"Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II","volume":"285","author":"Durrington","year":"2010","journal-title":"J Biol Chem"},{"key":"2026021904210465300_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1513\/pats.201002-024AW","article-title":"Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension","volume":"7","author":"Li","year":"2010","journal-title":"Proc Am Thorac Soc"},{"key":"2026021904210465300_bib50","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/hmg\/ddn214","article-title":"Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue","volume":"17","author":"Sobolewski","year":"2008","journal-title":"Hum Mol Genet"},{"key":"2026021904210465300_bib51","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1164\/rccm.200908-1284OC","article-title":"Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation","volume":"181","author":"Girerd","year":"2010","journal-title":"Am J Respir Crit Care Med"}],"container-title":["American Journal of Respiratory Cell and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/49\/3\/403\/66893711\/ajrcmb_49_3_403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/49\/3\/403\/66893711\/ajrcmb_49_3_403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:24:14Z","timestamp":1771493054000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article\/49\/3\/403\/8483074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,9,1]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.1165\/rcmb.2013-0100oc","relation":{},"ISSN":["1044-1549","1535-4989"],"issn-type":[{"value":"1044-1549","type":"print"},{"value":"1535-4989","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,9]]},"published":{"date-parts":[[2013,9,1]]}}}